SELLAS Life Sciences Group, Inc.

1. 01

   Ahead of SPY and its sector fund XLV over 1 year

   1 month: −19.4% (SPY −1.6%, XLV +13.5%). 3 months: −22.9% (SPY −0.4%, XLV +15.5%). 1 year: +450.6% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: SLS, SPY and XLV · as of 4 Nov 2026

2. 02

   Below its 50-day average, above its 200-day

   The 4 Nov 2026 close of $9.14 was 22.6% below its 50-day average ($11.81) and 5.7% above its 200-day average ($8.64). It has closed above the 200-day for 2 sessions, since 3 Nov 2026. The 50-day average crossed above the 200-day on 20 Mar 2025, 409 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

3. 03

   11.9 days to cover short interest

   53.8M shares were sold short at the 15 Oct 2026 settlement, 26.6% of the 201.9M shares outstanding; covering them would take 11.9 days of average volume. Short interest is reported twice a month, on a lag.

   Exchange short-interest filing · as of 15 Oct 2026

4. 04

   Volume 2.3× its 30-session average on 2 Nov 2026

   2 Nov 2026 volume of 14.4M shares was 2.3× the average of the 30 sessions before it (6.2M), as the price fell 11.7%. SPY traded 1.2× its own average that session.

   Daily volume against a 30-session baseline · as of 2 Nov 2026

5. 05

   53% of the way up its 52-week range

   Closed at $9.14 on 4 Nov 2026: 42.4% below the 52-week high of $15.88 (30 Jun 2026) and 557.6% above the low of $1.39 (2 Dec 2025).

   Daily price bars, split-adjusted · as of 4 Nov 2026

At the 4 Nov 2026 close